Treatment of breakthrough fungal infections: Is there one best drug strategy?

  • Michael D. Nailor
  • Pranatharthi H. Chandrasekar


Widespread use of antifungal drugs in prophylactic and therapeutic settings is associated with breakthrough infections primarily due to Aspergillus and non-Aspergillus molds and non-albicans Candida. Reasons for breakthrough include worsening of initial infection, superinfection, and co-infection; subtherapeutic drug levels, emergence of antifungal resistance, and host factors may contribute to progression of the initial infection. Establishing an etiologic diagnosis is crucial because clinical and radiological features are nonspecific, and empirically chosen drug(s) may not provide appropriate antimicrobial coverage. Evidence-based data do not exist for the management of breakthrough infection. Current treatment strategies include switching therapy to a drug of another class, dose optimization, and combinations of drugs. Dosage adjustment of triazoles guided by serum concentrations may ensure optimal efficacy and avoidance of toxicity. A combination of an echinocandin plus a triazole or polyene appears to be synergistically effective against invasive aspergillosis. The treatment strategy needs to be individualized. For an optimal outcome, reversal of immunosuppression is essential.

References and Recommended Reading

  1. 1.
    Kontoyiannis DP, Marr K, Wannemuehler KA: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the TRANSNET Database [abstract M-1196]. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17–20, 2007.Google Scholar
  2. 2.
    Cornely OA, Maertens J, Winston DJ, et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348–359.CrossRefPubMedGoogle Scholar
  3. 3.
    Ullmann AJ, Lipton JH, Vesole DH, et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335–347.CrossRefPubMedGoogle Scholar
  4. 4.
    Wingard JR, Carter SL, Walsh TJ, et al.: Prospective, multicenter study comparing voriconazole with fluconazole as prophylaxis in allogeneic stem cell recipients [abstract 163]. Presented at the Annual Meeting of the American Society of Hematology. Atlanta, GA; December 8–11, 2007.Google Scholar
  5. 5.
    Escuissato DL, Gasparetto EL, Marchiori E, et al.: Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. Am J Roentgenol 2005, 185:608–615.Google Scholar
  6. 6.
    Marty FM, Cosimi LA, Baden LR, et al.: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350:950–952.CrossRefPubMedGoogle Scholar
  7. 7.
    Imhof A, Balajee SA, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743–746.CrossRefPubMedGoogle Scholar
  8. 8.
    Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350–1360.CrossRefPubMedGoogle Scholar
  9. 9.
    Trifilio SM, Bennett CL, Yarnold PR, et al.: Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425–429.CrossRefPubMedGoogle Scholar
  10. 10.
    Lekakis LJ, Lawson A, Prante J, et al.: Fatal Rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009, 15:991–995.CrossRefPubMedGoogle Scholar
  11. 11.
    Madureira A, Bergeron A, Lacroix C, et al.: Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007, 30:551–554.CrossRefPubMedGoogle Scholar
  12. 12.
    Van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin infect Dis 2006, 42:e61–e65.CrossRefPubMedGoogle Scholar
  13. 13.
    Ibrahim AS, Gebremariam T, Fu Y, et al.: Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008, 52:1556–1558.CrossRefPubMedGoogle Scholar
  14. 14.
    Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364–371.CrossRefPubMedGoogle Scholar
  15. 15.
    Ibrahim AS, Gebremariam T, Schwartz JA, et al.: Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009, 53:772–775.CrossRefPubMedGoogle Scholar
  16. 16.
    Spellberg B, Walsh TJ, Kontoyiannis DP, et al.: Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009, 48:1743–1751.CrossRefPubMedGoogle Scholar
  17. 17.
    Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327–360.CrossRefPubMedGoogle Scholar
  18. 18.
    Trifilio S, Singhal S, Williams S, et al.: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451–456.CrossRefPubMedGoogle Scholar
  19. 19.
    Howard SJ, Cerar D, Anderson MJ, et al.: Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15:1068–1076.CrossRefPubMedGoogle Scholar
  20. 20.
    Snelders E, van der Lee HA, Kuijpers J, et al.: Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008, 5:e219.CrossRefPubMedGoogle Scholar
  21. 21.
    Krishnan-Natesan S, Manavathu EK, Chandrasekar PH: Laboratory-selected voriconazole-resistant (VCZ-R) Aspergillus fumigatus: synergistic in vitro activity of the combination of voriconazole and anidulafungin (AFG) [abstract M-3764]. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–28, 2008.Google Scholar
  22. 22.
    Krishnan-Natesan S, Manavathu EK, Cutright JL, et al.: In vitro efficacy of posaconazole against laboratory-selected voriconazole-resistant A. fumigatus in a neutropenic murine pulmonary aspergillosis model [abstract M-1553]. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–28, 2008.Google Scholar
  23. 23.
    Caillot D, Thiebaut A, Herbrecht R, et al.: Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110:2740–2746.CrossRefPubMedGoogle Scholar
  24. 24.
    Caillot D, Couaillier JF, Bernard A, et al.: Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19:253–259.PubMedGoogle Scholar
  25. 25.
    Maertens J, Raad I, Petrikkos G, et al.; for the Caspofungin Salvage Aspergillosis Study Group: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563–1571.CrossRefPubMedGoogle Scholar
  26. 26.
    Kontoyiannis DP, Ratanatharathorn V, Young JA, et al.: Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009, 11:89–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Denning DW, Ribaud P, Milpied N, et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563–571.CrossRefPubMedGoogle Scholar
  28. 28.
    Walsh TJ, Raad I, Patterson TF, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Andes D: Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin N Am 2006, 20:679–697.CrossRefGoogle Scholar
  30. 30.
    Louie A, Deziel M, Liu W, et al.: Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005, 49:5058–5068.CrossRefPubMedGoogle Scholar
  31. 31.
    Wiederhold NP, Kontoyiannis DP, Chi J, et al.: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004, 190:1464–1471.CrossRefPubMedGoogle Scholar
  32. 32.
    Pappas PG, Rotstein CM, Betts RF, et al.: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883–893.CrossRefPubMedGoogle Scholar
  33. 33.
    Betts RF, Nucci M, Talwar D, et al.: A multicenter, double-blind trial of high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676–1684.CrossRefPubMedGoogle Scholar
  34. 34.
    Maertens J, Glasmacher A, Herbrecht R, et al.: Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888–2897.CrossRefPubMedGoogle Scholar
  35. 35.
    Lutsar I, Hodges MR, Tomaszewski K, et al.: The safety of voriconazole and dose individualization. Clin Infect Dis 2003, 36:1087–1088.CrossRefPubMedGoogle Scholar
  36. 36.
    Pascual A, Calandra T, Bolary S, et al.: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201–211.CrossRefPubMedGoogle Scholar
  37. 37.
    Smith J, Safdar N, Knasinski V, et al.: Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570–1572.CrossRefPubMedGoogle Scholar
  38. 38.
    Imhof A, Schaer DJ, Schwarz U, et al.: Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006, 136:739–742.PubMedGoogle Scholar
  39. 39.
    Cornely OA, Maertens J, Bresnik M, et al.: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmbiLoad trial). Clin Infect Dis 2007, 44:1289–1297.CrossRefPubMedGoogle Scholar
  40. 40.
    Rex JH, Pappas PG, Karchmet AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003, 36:1221–1228.CrossRefPubMedGoogle Scholar
  41. 41.
    Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA: Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005, 18:163–194.CrossRefPubMedGoogle Scholar
  42. 42.
    Philip A, Odabasi Z, Rodriguez J, et al.: In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005, 49:3572–3574.CrossRefPubMedGoogle Scholar
  43. 43.
    Viscoli C: Combination therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:803–805.CrossRefPubMedGoogle Scholar
  44. 44.
    Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834–1843.CrossRefPubMedGoogle Scholar
  45. 45.
    Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797–802.CrossRefPubMedGoogle Scholar
  46. 46.
    Denning DW, Marr KA, Lau WM, et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337–349.CrossRefPubMedGoogle Scholar
  47. 47.
    Cordonnier C, Maury S, Pautas C, et al.: Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004, 33:943–948.CrossRefPubMedGoogle Scholar
  48. 48.
    Martino R, Parody R, Fukuda T, et al.: Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006, 108:2928–2936.CrossRefPubMedGoogle Scholar
  49. 49.
    Cornely OA, Bohme A, Reichert D, et al.: Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008, 61:939–946.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Michael D. Nailor
  • Pranatharthi H. Chandrasekar
    • 1
  1. 1.Infectious DiseasesWayne State University, Harper University HospitalDetroitUSA

Personalised recommendations